Last reviewed · How we verify

Hexaxim® — Competitive Intelligence Brief

Hexaxim® (Hexaxim®) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Hexavalent vaccine. Area: Immunology.

phase 3 Hexavalent vaccine Immunology Biologic Live · refreshed every 30 min

Target snapshot

Hexaxim® (Hexaxim®) — Sanofi Pasteur, a Sanofi Company. Hexaxim is a hexavalent vaccine that provides immunization against six infectious diseases by stimulating the immune system to produce antibodies against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and Haemophilus influenzae type b.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Hexaxim® TARGET Hexaxim® Sanofi Pasteur, a Sanofi Company phase 3 Hexavalent vaccine
Hexyon vaccine Hexyon vaccine Sanofi phase 3 Hexavalent vaccine
Hexaxim Vaccine Hexaxim Vaccine Sanofi Pasteur, a Sanofi Company phase 3 Hexavalent vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Hexavalent vaccine class)

  1. Sanofi Pasteur, a Sanofi Company · 2 drugs in this class
  2. Sanofi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Hexaxim® — Competitive Intelligence Brief. https://druglandscape.com/ci/hexaxim. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: